Rhinomed (ASX:RNO) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

RNO Panoramica delle azioni

Rhinomed Limited engages in the research, development, and commercialization of consumer and medical devices worldwide.

RNO analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	2/6
Dividendi	0/6

Premi

Analisi del rischio

Earnings have declined by 8.2% per year over past 5 years

Does not have a meaningful market cap (A$12M)

Negative shareholders equity

Highly volatile share price over the past 3 months

Rhinomed Limited Concorrenti

Althea Group Holdings

ASX:AGH

AU$10.2m

Cann Group

ASX:CAN

AU$15.4m

AusCann Group Holdings

ASX:AC8

AU$17.6m

Nyrada

ASX:NYR

AU$10.0m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Rhinomed
Prezzi storici delle azioni
Prezzo attuale dell'azione	AU$0.04
Massimo di 52 settimane	AU$0.10
Minimo di 52 settimane	AU$0.019
Beta	0.88
1Variazione di 1 mese	60.00%
Variazione a 3 mesi	33.33%
Variazione di 1 anno	-55.56%
3Variazione a 3 anni	-66.67%
Variazione a 5 anni	-74.19%
Variazione dall'IPO	-99.41%

Notizie e aggiornamenti recenti

Rhinomed Limited's (ASX:RNO) CEO Will Probably Find It Hard To See A Huge Raise This Year

Nov 10

Recent updates

Rhinomed Limited's (ASX:RNO) CEO Will Probably Find It Hard To See A Huge Raise This Year

Nov 10

Rendimenti per gli azionisti

	RNO	AU Pharmaceuticals	AU Mercato
7D	-7.0%	0.9%	2.2%
1Y	-55.6%	52.4%	11.2%

Ritorno vs Industria: RNO underperformed the Australian Pharmaceuticals industry which returned 61.8% over the past year.

Rendimento vs Mercato: RNO underperformed the Australian Market which returned 9.6% over the past year.

Volatilità dei prezzi

Is RNO's price volatile compared to industry and market?
RNO volatility
RNO Average Weekly Movement	26.2%
Pharmaceuticals Industry Average Movement	10.1%
Market Average Movement	8.2%
10% most volatile stocks in AU Market	16.9%
10% least volatile stocks in AU Market	3.4%

Prezzo delle azioni stabile: RNO's share price has been volatile over the past 3 months.

Volatilità nel tempo: RNO's weekly volatility has increased from 19% to 26% over the past year.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2004	n/a	Michael Johnson	www.rhinomed.global

Rhinomed Limited Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Rhinomed con la sua capitalizzazione di mercato?
RNO statistiche fondamentali
Capitalizzazione di mercato	AU$11.51m
Guadagni(TTM)	-AU$10.91m
Ricavi(TTM)	AU$8.05m

1.4x

Rapporto P/S

-1.1x

Rapporto P/E

RNO è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
RNO Conto economico (TTM)
Ricavi	AU$8.05m
Costo del fatturato	AU$2.78m
Profitto lordo	AU$5.28m
Altre spese	AU$16.18m
Guadagni	-AU$10.91m

Ultimi guadagni dichiarati

Jun 30, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	-0.038
Margine lordo	65.53%
Margine di profitto netto	-135.49%
Rapporto debito/patrimonio netto	-90.4%

Come si è comportato RNO nel lungo periodo?

Vedi performance storica e confronto

RNO Panoramica delle azioni

Premi

Analisi del rischio

Rhinomed Limited Concorrenti

ASX:AGH

AU$10.2m

ASX:CAN

AU$15.4m

ASX:AC8

AU$17.6m

ASX:NYR

AU$10.0m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited Withdraws the Resolution for Re-Election of Ryan McIntyre as a Director

Rhinomed Limited's (ASX:RNO) CEO Will Probably Find It Hard To See A Huge Raise This Year

Rhinomed Limited Announces Retirement of Brent Scrimshaw, Non-Executive Director, Effective from November 17Th, 2023

Recent updates

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited Withdraws the Resolution for Re-Election of Ryan McIntyre as a Director

Rhinomed Limited's (ASX:RNO) CEO Will Probably Find It Hard To See A Huge Raise This Year

Rhinomed Limited Announces Retirement of Brent Scrimshaw, Non-Executive Director, Effective from November 17Th, 2023

Full year 2023 earnings released: AU$0.038 loss per share (vs AU$0.02 loss in FY 2022)

Rhinomed Limited, Annual General Meeting, Nov 17, 2023

Full year 2023 earnings released: AU$0.039 loss per share (vs AU$0.02 loss in FY 2022)

New minor risk - Financial data availability

New major risk - Market cap size

Insider recently bought AU$242k worth of stock

Insider recently bought AU$372k worth of stock

Is Rhinomed (ASX:RNO) Using Too Much Debt?

First half 2023 earnings released: AU$0.016 loss per share (vs AU$0.013 loss in 1H 2022)

Less than half of directors are independent

Rhinomed Limited, Annual General Meeting, Nov 18, 2022

Less than half of directors are independent

Rhinomed Limited Announces Rhinoswab Junior Study Confirms New Nasal Swab Is Most Accurate, Comfortable and Easy for Kids

Rhinomed Limited Appoints Lyn Swinburne AO as Non-Executive Director

Full year 2022 earnings released: AU$0.02 loss per share (vs AU$0.034 loss in FY 2021)

Rhinomed (ASX:RNO) Is In A Strong Position To Grow Its Business

Rhinomed Limited Announces the Interim Results in the World First "Rhinoswab for Diagnosis of Respiratory Virus in Children" Trial

CEO, MD & Executive Director exercised options to buy AU$855k worth of stock.

CEO, MD & Executive Director exercised options to buy AU$855k worth of stock.

Full year 2021 earnings released: AU$0.034 loss per share (vs AU$0.044 loss in FY 2020)

Full year 2021 earnings released: AU$0.034 loss per share (vs AU$0.044 loss in FY 2020)

Here's Why We're Not Too Worried About Rhinomed's (ASX:RNO) Cash Burn Situation

Non-Executive Director recently bought AU$77k worth of stock

Non-Executive Director recently bought AU$76k worth of stock

Here's Why We're Watching Rhinomed's (ASX:RNO) Cash Burn Situation

First half 2021 earnings released: AU$0.022 loss per share (vs AU$0.034 loss in 1H 2020)

Key Things To Understand About Rhinomed's (ASX:RNO) CEO Pay Cheque

Independent Non-Executive Chairman recently bought AU$180k worth of stock

Insider recently bought AU$435k worth of stock

How Many Rhinomed Limited (ASX:RNO) Shares Did Insiders Buy, In The Last Year?

Rhinomed Limited Detects SARS-CoV-2 in Doherty Inst. RT-PCR Study

Rhinomed Limited Announces Registration of Nasal Swab with Australian Therapeutic Goods Administration

Rhinomed Limited Announces Registration of Its Novel Nasal Swab with the US FDA

Insider recently bought AU$513k worth of stock

Insider recently bought AU$443k worth of stock

Insider recently bought AU$668k worth of stock

Insider recently bought AU$600k worth of stock

Rhinomed Limited Auditor Raises 'Going Concern' Doubt

Full year earnings released - AU$0.044 loss per share

Rendimenti per gli azionisti

Volatilità dei prezzi

Informazioni sull'azienda

Rhinomed Limited Riepilogo dei fondamenti

1.4x

-1.1x

Guadagni e ricavi